{"id":"NCT02662764","sponsor":"Talphera, Inc","briefTitle":"Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg","officialTitle":"A Multicenter, Open-Label Trial to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-28","primaryCompletion":"2017-04-14","completion":"2017-05-05","firstPosted":"2016-01-26","resultsPosted":"2018-08-08","lastUpdate":"2018-08-08"},"enrollment":320,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Moderate-to-severe Acute Pain"],"interventions":[{"type":"DRUG","name":"Zalviso™ 15 mcg","otherNames":["Zalviso™ (sufentanil sublingual tablet system) 15 mcg"]}],"arms":[{"label":"Zalviso™ 15 mcg","type":"EXPERIMENTAL"}],"summary":"Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg","primaryOutcome":{"measure":"Percentage of Patients Who Experienced at Least One System-generated Error Based on the Controller Data While Using the Zalviso System","timeFrame":"Up to 72 hours","effectByArm":[{"arm":"Zalviso™ 15 mcg","deltaMin":2.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":320},"commonTop":["Nausea","Hypotension","Vomiting","Muscle spasms","Oxygen saturation decreased"]}}